Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

Posted by on Feb 7th, 2025

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a report published on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

BCLI stock opened at $1.83 on Thursday. The company’s 50-day moving average is $1.98 and its 200-day moving average is $2.82. The stock has a market capitalization of $10.43 million, a PE ratio of -0.38 and a beta of 0.26. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89.

About Brainstorm Cell Therapeutics

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Recommended Stories

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.